Allergy

Allergy treatment use increases postpartum depression risk in women with allergic rhinitis, a study found.

Q1 2025 allergy updates: FDA approved the first omalizumab biosimilar, and experts shared insights on peanut immunotherapy and food allergy treatments.

Aquestive’s Anaphylm study showed positive pharmacokinetic results in children and adolescents, supporting its FDA submission.

March Allergy Updates: FDA approved the first biosimilar for omalizumab, epicutaneous and oral immunotherapy trials showed promise, and experts discussed allergy trends.

A study found many anaphylaxis patients didn’t receive adrenaline, the first-line treatment. Adrenaline use correlated with better outcomes in adults and children.

A new study found that the time it takes to diagnose alpha-gal syndrome has improved from 5.3 years to 28 days since 2011, but disparities remain based on education level.

A study found that genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.

Patients with hereditary angioedema report greater rates of autoimmune diseases, allergies, and asthma than the general population, highlighting key comorbidities.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

Climate change worsens allergies by lengthening pollen seasons, increasing air pollution, and driving new food allergies. Experts offer strategies for clinicians.

A study highlights how food allergies impact adults' mental health and social lives, revealing anxiety, isolation, and the need for better support systems.

Lugar spoke with HCPLive about when to refer patients with suspected ISM to an allergist, highlighting allergic manifestations, diagnostic clues, and misconceptions.

HCPLive spoke with Lugar on indolent systemic mastocytosis’ allergic manifestations and diagnostic markers.

The phase 3 REALISE study found EPIT with VP250 had a strong safety profile, with severe adverse events dropping from 9.7% in year 1 to 0.3% in year 3.

A narrative review reports the connection between allergies and sleep and available treatment options for both conditions.

Among 162 patients in the study, 99% reported satisfaction of sublingual immunotherapy with real grocery store food.

A cross-sectional cohort study identified several factors linked to eyewash use among individuals with allergic rhinitis.

In this video, part 5 of a 5-part series, panelists discuss emerging innovations in food allergy and anaphylaxis research poised to reshape clinical practice.

In this video, part 4 of a 5-part series, panelists discuss gaps in clinician education regarding food allergies and anaphylaxis.

In this video, part 2 of a 5-part series, panelists discuss unmet needs in pediatric food allergy research and clinical care.

In this video, part 1 of a 5-part series, panelists discuss on recent advancements in pediatric food allergy and anaphylaxis management.

Tezepelumab significantly reduced nasal polyp severity in CRSwNP patients during the phase 3 WAYPOINT trial, lowering the need for surgery by 92%.

At AAAAI 2025, HCPLive spoke with Craig about recognizing and treating hereditary angioedemia.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.